000 | 01894 a2200505 4500 | ||
---|---|---|---|
005 | 20250516093048.0 | ||
264 | 0 | _c20120926 | |
008 | 201209s 0 0 eng d | ||
022 | _a1470-8728 | ||
024 | 7 |
_a10.1042/BJ20120820 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSun, Haiyan | |
245 | 0 | 0 |
_aNitric oxide-dependent CYP2B degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2. _h[electronic resource] |
260 |
_bThe Biochemical journal _cAug 2012 |
||
300 |
_a377-82 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xmetabolism |
650 | 0 | 4 |
_aCysteine Endopeptidases _xmetabolism |
650 | 0 | 4 |
_aCytochrome P-450 CYP2B1 _xmetabolism |
650 | 0 | 4 | _aGenes, Tumor Suppressor |
650 | 0 | 4 |
_aHepatocytes _xdrug effects |
650 | 0 | 4 | _aIn Vitro Techniques |
650 | 0 | 4 |
_aInterleukin-1 _xpharmacology |
650 | 0 | 4 | _aKinetics |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMetabolic Networks and Pathways |
650 | 0 | 4 | _aModels, Biological |
650 | 0 | 4 |
_aNG-Nitroarginine Methyl Ester _xpharmacology |
650 | 0 | 4 |
_aNitric Oxide _xmetabolism |
650 | 0 | 4 |
_aNitric Oxide Donors _xpharmacology |
650 | 0 | 4 |
_aNitric Oxide Synthase Type II _xantagonists & inhibitors |
650 | 0 | 4 | _aNuclear Proteins |
650 | 0 | 4 |
_aProteasome Endopeptidase Complex _xmetabolism |
650 | 0 | 4 | _aProteasome Inhibitors |
650 | 0 | 4 | _aRats |
650 | 0 | 4 | _aRats, Inbred F344 |
650 | 0 | 4 |
_aSteroid Hydroxylases _xmetabolism |
700 | 1 | _aLee, Choon-myung | |
700 | 1 | _aTripathi, Shweta | |
700 | 1 | _aKim, Kyung-Bo | |
700 | 1 | _aMorgan, Edward T | |
773 | 0 |
_tThe Biochemical journal _gvol. 445 _gno. 3 _gp. 377-82 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1042/BJ20120820 _zAvailable from publisher's website |
999 |
_c21797511 _d21797511 |